Sign in
Taking peopleNo phase

TaVNS for Acute Intracerebral Hemorrhage

Key facts

Who runs it
Beijing Tiantan Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
186 people, planned
Started
15 Sept 2025
Expected to end
Dec 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • transcutaneous auricular vagus nerve stimulation device
  • Sham device
Record updated
15 January 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (22)Hide the full registry criteria

Who can take part

  • Patients with spontaneous supratentorial intracerebral hemorrhage
  • Age between 18 and 80 years
  • Onset within 72 hours
  • Hematoma volume between 5 and 40 mL
  • Glasgow Coma Scale (GCS) score greater than 8
  • Written informed consent obtained from the patient or their legal representative

Who cannot take part

  • Planned surgical treatment within 24 hours
  • Use of medications that interfere with autonomic function (e.g., beta-blockers, theophylline, tricyclic antidepressants, or steroids) within 7 days before screening
  • Secondary intracerebral hemorrhage (e.g., traumatic, tumor-related, vascular malformation, aneurysm, or coagulopathy-related)
  • Primary intraventricular hemorrhage
  • Parenchymal hemorrhage that ruptures into the ventricles, with blood completely filling one lateral ventricle, the third ventricle, the fourth ventricle or more than half of both lateral ventricles
  • Progressive neurological or other severe diseases
  • Pre-existing disability caused by previous illnesses: Modified Rankin Scale (mRS) score ≥ 3
  • Patients with severe cardiomyopathy, heart failure, pacemaker implantation, atrial fibrillation, frequent premature beats, second-degree or higher atrioventricular block, or other severe arrhythmias
  • Severe pulmonary disease, liver disease, renal insufficiency (glomerular filtration rate < 30 mL/min), active gastrointestinal bleeding, or malignant tumors with an expected survival of less than 3 months
  • Patients with hyperthyroidism, hypothyroidism, syncope, epilepsy, multiple sclerosis, Parkinson's disease, multiple system atrophy, or other known disorders affecting autonomic nervous function
  • Patients who cannot tolerate taVNS
  • Congenital or acquired ear abnormalities preventing taVNS treatment
  • Inability to comply with 10 days of treatment
  • Pregnancy or within 30 days of delivery
  • Participation in another interventional clinical trial
  • Inability to obtain written informed consent from the participant or their legal representative

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Intracerebral hemorrhage

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) in patients with acute intracerebral hemorrhage (ICH). The taVNS intervention will be delivered using the BS-TVNS800-1 transcutaneous electrical stimulation therapy device (KERFUN, Shanxi, China). A total of 186 patients will be randomly assigned in a 1:1 ratio to either the taVNS group or the sham-taVNS group. The primary outcome is the relative volume of perihematoma edema assessed on day 10-14 after randomization. Adverse events associated with taVNS therapy will be systematically evaluated to assess its safety profile.

The 2 groups in the trial

  • taVNS interventionExisting treatment, for comparison

    Patients will receive taVNS therapy twice daily for 10 consecutive days, in addition to receiving guideline-adherent conventional treatment during hospitalization.

    Treatment: transcutaneous auricular vagus nerve stimulation device

  • Sham taVNS interventionSham treatment, for comparison

    Patients will receive sham taVNS twice daily for 10 consecutive days, in addition to receiving guideline-adherent conventional treatment during their hospital stay.

    Treatment: Sham device

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Acute Intracerebral Hemorrhage
Criteria questions
Built from NCT06918964, who can take part
Record updated
15 January 2026